Ignite Creation Date:
2025-12-25 @ 4:48 AM
Ignite Modification Date:
2025-12-26 @ 3:50 AM
Study NCT ID:
NCT05995418
Status:
UNKNOWN
Last Update Posted:
2023-08-16
First Post:
2023-07-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study on the Health Economic Burden of Alzheimer's Disease in China
Sponsor:
Xuanwu Hospital, Beijing
Organization:
Study Overview
Official Title:
Monetary Costs of Alzheimer's Disease in China: Protocol for a Cluster-randomized Observational Study
Status:
UNKNOWN
Status Verified Date:
2023-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a multi-center and cross-sectional study. Using standardized case report forms, we randomly selected suitable patients from the cognitive centers of provincial administrative units in Chinese mainland to conduct a questionnaire survey, so as to obtain relevant information about their economic burden.
Detailed Description:
Under the policy background of building a national cognitive center, this study collected and evaluated the socio-demographic characteristics, geographical location, regional socio-economic development level, family support, medical resources, related behaviors, nursing environment, patients' health behaviors, current medical history, past history, drug use, family history and clinical diagnosis of Alzheimer's patients in inland provinces and cities of China, and made statistics on the related information of patients' health economics. To form a comprehensive assessment of the health economic burden of Alzheimer's disease in China, the primary objectives of the study are as follows:
1. Comprehensively assess the health economic burden of Alzheimer's disease, including medical and non-medical costs.
2. Explore the economic burden of Alzheimer's disease in different stages, including mild cognitive impairment stage, mild to moderate Alzheimer's disease stage and severe Alzheimer's disease stage.
3. To explore the health economic burden of the comorbidity of Alzheimer's disease and other chronic diseases.
1. Comprehensively assess the health economic burden of Alzheimer's disease, including medical and non-medical costs.
2. Explore the economic burden of Alzheimer's disease in different stages, including mild cognitive impairment stage, mild to moderate Alzheimer's disease stage and severe Alzheimer's disease stage.
3. To explore the health economic burden of the comorbidity of Alzheimer's disease and other chronic diseases.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: